Response from Medicines for Ireland (MFI) to new Framework Agreement on Supply and Pricing of Medicines 2021-2025

 

‘We welcome the new Supply and Pricing of Medicines Framework announced by Minister Donnelly. We believe, as the representative of the companies who supply the majority of medicines in Ireland daily, this agreement will bring increased patient access to generic and biosimilar medicines in Ireland, offering patients and healthcare professionals more choice, and yielding substantial savings to the State over the years ahead.’’

Padraic O’Brien, Chairperson, Medicines for Ireland

 

“This is a transformational agreement that will ensure even greater access to generic and biosimilar medicines in Ireland. The Minister, the HSE, the Department of Health and our member companies have worked tirelessly to make this new Agreement a reality, ensuring the focus remained on patient access to medicines. The Agreement is a positive step forward, bringing patients in Ireland earlier access to best value biosimilar and generic medicines in their patient journey.’’

David Delaney, Director, Medicines for Ireland.